TLR2 and cancer: For TLR2 polymorphism (−196 to −174 del), the meta-analysis showed a significantly increased risk for all cancers (allele comparison: OR = 1.62, 95% CI: 1.09–2.43, P<0.001 for heterogeneity test; dominant model: OR = 1.64, 95% CI: 1.04–2.60, P<0.001 for heterogeneity test; recessive model: OR = 2.28, 95% CI: 1.23–4.20, P<0.001 for heterogeneity test).